{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:42:10Z","timestamp":1774939330026,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hunan Public Health Alliance","award":["SXSW2021006"],"award-info":[{"award-number":["SXSW2021006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Managing multidrug-resistant (MDR) HIV infections in children is particularly challenging due to the lack of experience with new drugs in the pediatric setting. Second-line albuvirtide (ABT) with an optimized antiretroviral background therapy was approved for adults and adolescents after first-line treatment failure. This paper describes the treatment outcomes and adverse effects of an ABT-based dual-active antiretroviral treatment regimen in a child with MDR HIV strains.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 13 year-old Chinese female patient infected with MDR HIV strains showed a decrease in viral load (from 4.48 log10 to 1.73 log10) and an increase in CD4\u2009+\u2009T cells (from 15 to 308 cells\/\u00b5l) after 12 months of treatment with an ABT-based antiretroviral regimen. The child showed no relevant drug-related adverse reactions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The case reported here could suggest that an ABT-based antiretroviral therapy might be beneficial and without relevant toxicity in children with MDR HIV. Infectiologists specializing in managing HIV should be prepared to manage an increasing number of children with MDR HIV. ABT might be a new treatment option for MDR HIV infection in children.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-023-00560-w","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:02:12Z","timestamp":1693202532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Wei","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-yun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"560_CR1","unstructured":"UNICEF Data. : Global and regional trends. https:\/\/data.unicef.org\/topic\/hivaids\/global-regional-trends\/. Accessed July 2022."},{"issue":"8","key":"560_CR2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/jac\/dku104","volume":"69","author":"P Rojas S\u00e1nchez","year":"2014","unstructured":"Rojas S\u00e1nchez P, Holgu\u00edn A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. J Antimicrob Chemother. 2014;69(8):2032\u201342.","journal-title":"J Antimicrob Chemother"},{"issue":"9777","key":"560_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(11)60208-0","volume":"377","author":"H Castro","year":"2011","unstructured":"Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (London England). 2011;377(9777):1580\u20137.","journal-title":"Lancet (London England)"},{"key":"560_CR4","unstructured":"WHO. : Global action plan on HIV drug resistance 2017\u20132021: 2018 Progress report. 2018."},{"issue":"3","key":"560_CR5","doi-asserted-by":"publisher","first-page":"e32599","DOI":"10.1371\/journal.pone.0032599","volume":"7","author":"H Chong","year":"2012","unstructured":"Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS ONE. 2012;7(3):e32599.","journal-title":"PLoS ONE"},{"issue":"3","key":"560_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jinf.2022.05.034","volume":"85","author":"B Su","year":"2022","unstructured":"Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, et al. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. J Infect. 2022;85(3):334\u201363.","journal-title":"J Infect"},{"issue":"18","key":"560_CR7","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1001\/archinte.163.18.2187","volume":"163","author":"GR Kaufmann","year":"2003","unstructured":"Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the swiss HIV Cohort Study. Arch Intern Med. 2003;163(18):2187\u201395.","journal-title":"Arch Intern Med"},{"issue":"5","key":"560_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/hiv.12004","volume":"14","author":"C Stephan","year":"2013","unstructured":"Stephan C, Hill A, Sawyer W, van Delft Y, Moecklinghoff C. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*. HIV Med. 2013;14(5):284\u201392.","journal-title":"HIV Med"},{"issue":"12","key":"560_CR9","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1093\/jac\/dkx300","volume":"72","author":"F Raffi","year":"2017","unstructured":"Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, et al. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. J Antimicrob Chemother. 2017;72(12):3425\u201334.","journal-title":"J Antimicrob Chemother"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00560-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:31:16Z","timestamp":1700321476000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00560-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00560-w","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments. Written informed consent was obtained from a legal guardian. A statement on ethics approval and consent were included. Approved scientific research papers by medical ethics committee of the First Hospital of Changsha.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}